Regulatory T cells (T regs ) can suppress a wide variety of cell types, in diverse organ sites and inflammatory conditions. Whereas T regs possess multiple suppressive mechanisms, the number required for maximal function is unclear. Furthermore, whether any interrelationship or cross-regulatory mechanisms exist to orchestrate and control their utilization is unknown. In this study, we assessed the functional capacity of T regs lacking the ability to secrete both IL-10 and IL-35, which individually are required for maximal T reg activity. Surprisingly, IL-10/IL-35 double-deficient T regs were fully functional in vitro and in vivo. Loss of IL-10 and IL-35 was compensated for by a concurrent increase in cathepsin E (Ctse) expression, enhanced TRAIL (Tnfsf10) expression, and soluble TRAIL release, rendering IL-10/IL-35 double-deficient T regs functionally dependent on TRAIL in vitro and in vivo. Lastly, whereas C57BL/6 T regs are normally IL-10/IL-35 dependent, BALB/c T regs , which express high levels of cathepsin E and enhanced TRAIL expression, are partially TRAIL dependent by default. These data reveal that cross-regulatory pathways exist that control the utilization of suppressive mechanisms, thereby providing T reg functional plasticity. The Journal of Immunology, 2011, 187: 000-000.
R egulatory T cells (T regs ) play a key role in maintaining immune tolerance, preventing autoimmune diseases, and limiting inflammatory conditions (1-3). A unique and important feature of T regs is the brevity and flexibility of their regulatory capacity. T regs can suppress an array of different cell types [including CD4
+ T cells (Th1/Th2/Th17) (4), CD8 + T cells (5), B cells (4, 6) , dendritic cells (7), and osteoclasts (8) ] in a variety of inflammatory conditions and in distinct tissue locations. The ability of T regs to suppress a broad range of targets in a variety of scenarios can be attributed to the numerous mechanisms employed by T regs to mediate their function (2, 9) . However, it is not clear whether all these mechanisms are equally important or whether they have nonredundant roles under different inflammatory settings. Indeed, it was recently reported that T regs may have specialized mechanisms for controlling specific cell types, as T regs appear to require IFN regulatory factor-4, T-bet, and STAT3 to suppress Th2, Th1, and Th17 cells, respectively (10) (11) (12) . However, it is unclear which T reg mechanisms are used under specific conditions, how many mechanisms are required for maximal T reg function, and whether there is any crosstalk between the various regulatory mechanisms used. Although it is well established that Foxp3 is a key transcription factor critical for the stability of T regs (13) , whether there is stability or plasticity in the regulatory mechanisms used by T regs is unclear.
T regs use multiple mechanisms to mediate their function, with the immunosuppressive cytokines TGF-b, IL-10, and IL-35 contributing significantly (14) (15) (16) . IL-10 is important for T reg function in vitro and in vivo, especially in the gut (17, 18) . IL-35 is a recently discovered heterodimeric cytokine composed of Ebi3 (also part of and Il12a/p35 (also part of IL-12) that is uniquely expressed by T regs , but not by T conventional (T conv ) cells, and is required for maximal T reg function (16) . Whereas the loss of either IL-10 or IL-35 significantly reduces T reg function, they do not become completely dysfunctional and deficient mice do not exhibit the lethal multiorgan inflammatory disease seen in Scurfy or Foxp3 2/2 mice that lack T regs (19, 20) . Thus, in the current study, we speculated that T regs that lacked both IL-10 and IL-35 might exhibit a more profound functional defect and that this approach could be used to assess the relative contributions of different suppressive mechanisms. Alternatively, given the importance of T regs in the maintenance of immune homeostasis, as yet unknown compensatory mechanisms may be triggered that attempt to restore immune balance. These possibilities were tested in this study.
Materials and Methods

Mice Ebi3
2/2 mice (C57BL/6; now 100% C57BL/6 by microsatellite analysis performed by Charles River) were provided by R. Blumberg and T. Kuo (Brigham and Women's Hospital, Boston, MA); Il10 2/2 mice were provided by T. Geiger (St. Jude Children's Research Hospital, Memphis, TN); + CD45RB low ) from spleens and lymph nodes of either knockout or wild-type C57BL/6 mice were positively sorted by FACS following staining with fluorochrome-conjugated Abs: anti-mouse CD4, anti-mouse CD45RB, and anti-mouse CD25 (BioLegend, San Diego, CA). The cells were sorted on a Reflection (i-Cyt, Champaign, IL) or on a MoFlo (DakoCytomation, Fort Collins, CO). For flow cytometric analysis, purified T regs were cultured as described and stained with anti-TRAIL PE Ab (eBioscience, San Diego, CA) at the indicated time points after culture in presence of rIL-2 (1000 IU/ml). Cathepsin E (CTSE) intracellular staining was performed, as previously described (21) . Briefly, freshly isolated T regs were fixed with formaldehyde and permeabilized with Triton X-100 for 2 min prior to staining with anti-CTSE Ab (R&D Systems). Cells were analyzed on a FACSCalibur (Beckman Coulter, Brea, CA), and data were analyzed using FlowJo.
mRNA isolation, cDNA synthesis, and quantitative PCR Purified T regs from wild-type C57BL/6 mice or knockout mice were activated in the presence of anti-CD3-and anti-CD28-coated beads or cultured in combination with T conv cells at 4:1 (T conv :T regs ) ratio for 48 h. Where indicated for TRAIL expression, cells were activated in presence of IL-2 (1000 IU/ml), and cells were collected from RNA isolation at indicated time points. Cells were resorted based on their congenic markers, where indicated. RNA was isolated using Qiagen micro or mini RNA kit following manufacturer's instructions. RNA was quantified using a nanodrop spectrophotometer, and equal amount of total RNA in each sample was reverse transcribed with the high-capacity cDNA reverse-transcription kit (Applied Biosystems) following the manufacturer's guidelines. TaqMan primers and probes were designed with Primer Express software and were synthesized by the St. Jude Hartwell Center for Biotechnology and Bioinformatics. The primers for CTSE were CTSE forward, 59-CAA-CCTCTGGGTCCCTTC-39; CTSE reverse, 59-TGATTCCCTACCTCCG-TG-39; and CTSE probe, 59-CATGCAAGGCACACCCAG-39. The primers for TRAIL-R2 (DR5) were TRAIL-R2 (DR5) forward, 59-TGCTGCTCA-AGTGGCGC-39; DR5 reverse, 59-GGCATCCAGCAGATGGTTG-39; TRAIL forward, 59-CCTCTCGGAAAGGGCATTC-39; TRAIL reverse, 59-TCCT-GCTCGATGACCAGCT-39; actin forward, 59-ACCCACACTGTGCCCA-TCTAC-39; actin reverse, 59-AGCCAAGTCCAGACGCAGG-39; and actin probe, 59-AGGGCTATGCTCTCCCTCACGCCA-39. Equal volume of cDNA samples was used in a quantitative real time PCR (qPCR) reaction with primer probes and amplified for 40 cycles using an Applied Biosystems Prism 7900 Sequence Detection System instrument, according to the manufacturer's protocol. Relative quantification of mRNA expression was carried out using the comparative critical threshold method, as described in the Applied Biosystems User Bulletin number 2 (http://docs. appliedbiosystems.com/pebiodocs/04303859.pdf). In this study, the amount of target mRNA is normalized to the endogenous b-actin expression and is calculated by the equation 2 DDCT .
Immunoprecipitation and Western blotting
Immunoprecipitation and immunoblotting for CTSE were performed, as previously described (21) . T conv , wild-type, or knockout T regs were purified from spleens, as described. Equal numbers of natural T regs and T conv cells were lysed with lysis buffer. To all supernatants, lysis buffer containing 0.1% Tween 20, 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, and 1 complete protease inhibitor tablet (Roche, Indianapolis, IN) per 50 ml lysis buffer was added. Supernatants were immunoprecipitated with anti-mouse CTSE (R&D Systems) and protein G-Sepharose beads.
Immunoprecipitates were resolved by 10% SDS-PAGE (Invitrogen Life Technologies), and blots were probed with an anti-goat HRP secondary Ab (Amersham Biosciences). Blots were developed using ECL (Amersham Biosciences) and autoradiography.
Preparation of anti-CD3/CD28-coated latex beads
The 4 mM sulfate latex beads (Molecular Probes) were incubated overnight at room temperature with rotation in a 1:4 dilution of anti-CD3 and anti-CD28 Ab mix (13.3 mg/ml anti-CD3 [murine clone 145-2c11 and 26.6 mg/ ml anti-CD28 murine clone 37.51]; eBioscience). Beads were washed three times with 5 mM phosphate buffer (pH 6.5) and resuspended at 5 3 10 7 /ml in sterile phosphate buffer with 2 mM BSA.
In vitro T reg suppression assay and Transwell T reg assay
In vitro T reg suppression assays were performed, as described previously (16, 17, 22) . Anti-CD3-and anti-CD28-coated beads used for T cell stimulation in these assays were prepared, as described previously (17, 22) . Briefly, T conv and T regs from wild-type C57BL/6, Ebi3 In vitro Transwell suppression assays were performed, as described previously, to assess the ability of T regs to suppress via soluble mediators (17, 22 
T reg -mediated control of homeostatic expansion
Homeostasis assays were performed, as described previously (16, 23 ) and T regs (5 3 10 5 ) were resuspended in 0.5 ml PBS plus 2% FBS and injected i.v. into Rag1 2/2 mice. Where indicated, the mice were injected on days 0 and 3 with anti-TRAIL Ab (0.3 mg; provided by T. Griffith, University of Iowa) or isotype control Ab (0.3 mg; R&D Systems). Mice were euthanized 7 d post-transfer, and splenocytes were counted, stained, and analyzed by flow cytometry using Abs against CD4, Thy1.1, Thy1.2 (BioLegend), and Foxp3 (BD Biosciences). For each group, six to eight mice were analyzed.
Inflammatory bowel disease model
A recovery model of colitis/inflammatory bowel disease (IBD) was used, with some modifications (14, 23). Briefly, Rag1 2/2 mice were injected i.v.
with 0.5 3 10 6 wild-type or DR5 2/2 (CD4 + CD45RB
high CD25 2 ) naive T conv cells to induce IBD. Mice were weighed at the time of injection (time 0) and every week on the same day. At the onset of clinical symptoms of colitis (∼4 wk post-T conv cell transfer), the mice were divided into T reg recipient or no T reg control groups. Purified T regs from wild-type, Ebi3 2/2 , Il10 2/2 , or Ebi3
Il10 2/2 were injected i.p. All mice were weighed weekly and euthanized 32 d after the initial T cell transfer. In experimental mice, the colons were collected and fixed in 10% neutral-buffered formalin 4 wk after T reg injection. The tissues were further processed, and 4-mm sections were cut and stained with H&E. Pathology of the large intestine was scored in a blinded manner using a semiquantitative scale, as described previously (23) . In summary, grade 0 was assigned when no changes were observed; grade 1, minimal inflammatory infiltrates present in the lamina propria with or without mild mucosal hyperplasia; grade 2, mild inflammation in the lamina propria with occasional extension into the submucosa, focal erosions, minimal to mild mucosal hyperplasia, and minimal to moderate mucin depletion; grade 3, mild to moderate inflammation in the lamina propria and submucosa occasionally transmural with ulceration and moderate mucosal hyperplasia and mucin depletion; grade 4, marked inflammatory infiltrates commonly transmural with ulceration, marked mucosal hyperplasia and mucin depletion, and multifocal crypt necrosis; grade 5, marked transmural inflammation with ulceration, widespread crypt necrosis, and loss of intestinal glands.
Foxp3
2/2 rescue model
The Foxp3 2/2 rescue model was performed, as described previously (23). Briefly, wild-type or knockout T regs purified by FACS were injected (10 6 
2/2 mice. Recovery from disease was monitored weekly and reported as a clinical score. Five macroscopic categories were used to generate a 6-point scoring system. Mice were scored on the first four categories based on whether they showed (score of 1) or did not show (score of 0) the following characteristics: body size runted; tail is scaly and/or with lesions; ears small and scaly with or without lesions; and eyelids scaly and/or not fully open. The final scoring parameter was monitoring the activity level of the mouse. A score of 0 was assigned if the mouse was normal. A score of 1 was assigned if the mouse's activity was moderately impaired, and a score of 2 was assigned if the mouse was immobile. A combined score of 4 or greater was assigned moribund for longevity. Mice were euthanized 25 d posttransfer, spleen cells were counted and stained, and cell numbers were determined by flow cytometry. Lung, liver, and ear pinna were prepared for H&E analysis, and the severity of inflammation was assessed and scored in a blinded manner by an experienced veterinary pathologist. The scoring system used for assessing inflammation was based on a simple algorithm for expressing inflammatory infiltrates in the lungs, liver, and ear. The scores allotted to these three tissues were 0-9, 0-11, and 0-8, respectively, giving a maximum possible total of 28. Scoring criteria for each organ was as follows. The lung score was based upon inflammation in the peribronchiolar region, perivascular region, or interstitium. A score of 0-3 was assigned to each category, with 0 being minimal or no inflammation, and scores of 1, 2, or 3 indicative of ,10, 10-50, or .50%, respectively. The liver was scored based on three criteria. First was the degree of portal tract inflammation, with a score of 0 assigned to minimal or no inflammation. A score of 1, 2, or 3 was assigned if inflammation was associated with ,25, 25-75, or .75% of the liver portal tracts, respectively. The second criteria related to portal/periseptal interface hepatitis. A focus of interface hepatitis associated with either a few or most of the portal tracts was scored 1 and 2, respectively. Two or more foci of interface hepatitis surrounding ,50 or .50% of the portal tracts or periseptae were scored 3 and 4, respectively. Third, foci of granulocytes and/or lymphocytes with or without necrotic hepatocytes that expand the sinusoid were considered foci of inflammation. The number of inflammatory foci in 10 contiguous original magnification 310 objective fields was counted and recorded as the average number of foci per 310 field and given a score of 0-4. A score of 0 was assigned when sinusoidal foci of inflammatory cells were absent. One focus or less per 310 field, 2-4 foci per 310 field, 5-10 foci per 310 field, and .10 foci per 310 field were scored 1, 2, 3, and 4 respectively. The ear pinna was similarly scored based on two parameters, as follows: the percentage of the ear dermis with inflammatory infiltrates and the intensity of the dermal inflammation. For percentage analysis, a score of 0 was assigned when the inflammatory cells in all segments were not beyond that of normal background level. A score of 1, 2, 3, or 4 was assigned when the average percentages for the segments were ,25, 25-50, 51-75, or .75%, respectively. The intensity of the inflammatory infiltrate in the dermis was assessed as being of a loose or dense nature. A score of 0 was assigned when inflammatory cells in the dermis were not beyond the normal background level. When all of the inflammation was of the loose nature, a score of 1 was assigned. When there was a mixture of loose and dense inflammatory cell infiltrates, a score of 2 was assigned when the loose form was dominant. A score of 3 was assigned when the dense form was dominant. A score of 4 was assigned when all of the inflammation was of a dense nature.
Affymetrix array and analysis
Wild-type or knockout T regs were purified by FACS and mRNA isolated using the Qiagen micro RNA kit (Qiagen). Quality was confirmed by UV spectrophotometry and by analysis on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Total RNA (100 ng) was processed in the Hartwell Center for Biotechnology and Bioinformatics according to the Affymetrix eukaryote two-cycle target-labeling protocol and arrayed on a Mouse-430v2 GeneChip array. The expression data from the Affymetrix U133 plus two arrays were analyzed as MAS 5.0 signal log-start transformed using the following formula: log signal = natural log (signal + 20). This transform improves data dispersion and normality, and stabilizes the variance of the data (24) . Statistical tests and batch effect removal were performed using Partek Genomics Suite (St. Louis, MO). The log 2 ratio of Ebi3
Il10
2/2 T reg to wild-type T reg was calculated, and the 20 most positively induced named genes were selected. The log 2 ratios are calculated in STATA/SE 11.0 (College Station, TX) by the following formula: log ratio A over B = log(exponentiation[mean log signal A]/ exponentiation[mean log signal b])/log (2). Minimum selected gene had a log ratio of 1.65, which is 3.14-fold induced. Log ratios of the Il10
2/2
T reg and the Ebi3 2/2 T reg with respect to wild type were also defined and plotted with the log ratio of Ebi3 2/2 Il10 2/2 T reg to wild type as a heat map using Spotfire Decision Site software (Fig. 3A ). The t tests were then applied to each probe set to compare the Ebi3 2/2 Il10 2/2 T reg with wildtype T reg and single knockout T reg samples and log 2 ratios were calculated. The p value from the t tests were then 2log 10 transformed to create the significance score seen in the x-axis of the volcano plot (Fig. 3B) . A second series of t tests was performed to compare T reg with T conv and to develop a T reg signature. Probe sets that had a p value , 10 25 , an absolute value log ratio of T reg versus T conv of at least 3 (log 2 ), and a defined gene name were selected for each category in the signature that the mean was found. If a gene name appeared more than once, then the mean data were averaged for that gene. The scores were calculated by finding the maximum and minimum values for each gene and then rescaling them from 0 to 1 by the following formula: score g = (observed mean g 2 minimum mean g )/ (maximum mean g 2 minimum mean g ) for each gene g. These gene scores were then sorted in descending order by the T reg :T conv log ratio that includes activated and resting cells and graphed as a heat map in Spotfire Decision Site (data not shown). The microarray data from this study have been submitted into the Gene Expression Omnibus repository, accession number GSE29262 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE29262).
Statistical analysis
Unless otherwise stated, a Student t test was used to determine statistical significance. All calculations were done using GraphPad software. A p value ,0.05 was considered significant.
Results
T regs that lack IL-10 and IL-35 maintain their suppressive activity
We first assessed the functional capacity of T regs that lacked the ability to secrete IL-10 or IL-35 by generating Ebi3 (Fig. 1A) . We have previously shown that if T regs are optimally stimulated by anti-CD3-and anti-CD28-coated beads and in contact with T conv cells in the upper chamber (insert) of a Transwell plate, they can suppress third-party T conv cells in the lower chamber across a semipermeable membrane (17) .
The Fig. 2A-C) . We also assessed the ability of these T reg populations to rescue immune homeostasis in mixed bone marrow chimeras generated using Fig. 2D, 2E ). In contrast, the Foxp3 or Il10 2/2 T regs , T conv cell expansion was significantly reduced (Fig. 1C) . Surprisingly, the capacity of Ebi3 (Fig. 1D, 1E, Supplemental Fig. 2F ). In contrast, the wild-type T reg recipients started to gain weight within 1 wk of transfer. Despite previous studies clearly demonstrating the inability of Ebi3 2/2 or Il10 2/2 T regs to cure colitis, weight gain and improved histological parameters were evident in the Ebi3 2/2 Il10 2/2 T reg recipients, suggesting that these double-inhibitory cytokinedeficient T regs had regained their regulatory potential (Fig. 1D,  1E , Supplemental Fig. 2F ).
To rule out the possibility that this regulatory restoration had occurred as a consequence of their development in the absence of IL-10 and IL-35 and/or due to alternate cell-extrinsic mechanisms, we directly compared the suppressive capacity of wild-type and Ebi3 2/2 Il10 2/2 T regs that had developed in the same environment.
To address this possibility, we generated mixed bone marrow chimeras with a 1:1 ratio of congenically marked Thy1. (Fig. 3A, 3B , data not shown).
The two notable exceptions were Ap1S3 (adaptor-related protein complex 1, s 3 subunit) and Ctse (Fig. 3A, 3B ). AP1S3 is the s subunit of the adaptor protein-1 complex that is a component of the clathrin-coated vesicles associated with the trans-Golgi network that mediate vesicular formation and transport (33 T regs compared with wild-type and Ebi3 2/2 T regs ( Fig. 3C -E, Supplemental Fig. 3A-C) . Interestingly, CTSE has been implicated in the cleavage and/or processing of TRAIL (Tnfsf10; TNF [ligand] superfamily, member 10) and its release from the cell surface (35, 36) . TRAIL is a suppressive molecule of the TNF superfamily that can function in its surface-bound form or as a soluble trimer (37, 38) . TRAIL can mediate apoptosis and programmed regulated necrosis (necroptosis) or suppress proliferation (37, 39 The Journal of Immunologyrelease of soluble TRAIL. To directly examine this possibility, 293T cells were transfected with expression plasmids encoding Ctse and/or Tnfsf10 and used to assess the ability of TRAIL to limit T cell proliferation. TRAIL transfectants limited T cell proliferation, and this was further enhanced in the presence of CTSE (Fig. 4) . These data suggest that CTSE may play a role in enhancing the function of TRAIL by either increasing its activity via processing or increasing the generation of soluble TRAIL. These data also raised the possibility that Ebi3 2/2 Il10 2/2 T regs are dependent on TRAIL for their suppressive activity, whereas wildtype T regs are not.
IL-10/IL-35-deficient T regs suppress via TRAIL
We first assessed whether there were any changes in the level or rate of TRAIL expression during activation of wild-type, Ebi3 2/2 ,
(TRAIL) mRNA expression were observed over time or between the four T reg populations (Supplemental Fig. 3D ). Whereas all T reg populations exhibited increased TRAIL surface expression following activation, Ebi3 2/2 Il10 2/2 T regs expressed significantly higher levels of TRAIL after 16 h, but not 24 h, postactivation (Fig. 5A , 5B, Supplemental Fig. 3E ). This suggested that the kinetics of TRAIL expression is accelerated in Ebi3 2/2 Il10
T regs . Interestingly, although IL-10 appeared to influence CTSE expression (Fig. 3C, 3E , Supplemental Fig. 3A-C) , IL-35 may influence other parameters that influence TRAIL expression, as Ebi3 2/2 T regs expressed slightly higher levels of TRAIL at 16 h compared with wild-type or Il10 2/2 T regs (Supplemental Fig. 3E ).
We then used various approaches to determine the extent to which this accelerated TRAIL expression meant that the Ebi3
Il10
2/2 T regs were dependent on TRAIL-mediated suppression.
TRAIL mediates its suppression in part via caspase-mediated apoptosis (37) . Thus, we asked whether Ebi3 2/2 Il10 2/2 T regs mediated suppression in a caspase-dependent fashion by performing a Transwell suppression assay in the presence of the general caspase inhibitor z-VAD-Fmk or a vehicle control (42) . Although wild-type T reg suppression was unaffected by z-VAD- 
Fmk or its DMSO vehicle control, Ebi3
2/2 Il10 2/2 T reg -mediated suppression was blocked (Fig. 5C ). These data suggest that Ebi3
Il10 2/2 T regs suppress T conv proliferation via a caspase-dependent pathway. TRAIL signaling in the mouse is mediated through DR5 (Tnfrsf10b; TNFR superfamily, member 10b; also known as TRAIL-R2) (43) . Therefore, we first asked whether the Ebi3 Isotype control Ab or anti-TRAIL was injected on days 0 and 3, and homeostatic expansion of the Thy1.1 + T conv cells was determined 7 d later. T conv cell expansion, wild-type T reg -mediated suppression, and T reg numbers were unaffected by the anti-TRAIL treatment (Fig. 6D, data not shown) . In striking contrast, TRAIL inhibition blocked the ability of Ebi3 Loss of IL-10 and IL-35 production by T regs led to increased CTSE expression and subsequent dependence on TRAIL-mediated suppression. We questioned the extent to which unmanipulated examples of this T reg functional plasticity might exist. Differential CTSE expression has been reported in different inbred mouse strains (21) . In particular, C57BL/6 mice express low levels of CTSE, whereas expression in BALB/c and 129 mice is high. We first confirmed these observations by assessing Ctse expression by qPCR and intracellular staining (Fig. 7A, 7B) . The results clearly indicate that BALB/c T regs express higher levels of CTSE, 
Discussion
T regs can function in diverse anatomical locations and in a wide variety of immunological and disease settings (46) . Consequently, the large array of suppressive mechanisms that T regs are reported to possess may help them maintain immune homeostasis under diverse scenarios. Indeed, T regs may have specialized mechanisms for controlling specific cell types as T regs appear to require IFN regulatory factor-4, T-bet, and STAT3 to suppress Th2, Th1, and Th17 cells, respectively (10) (11) (12) . However, this may have a greater influence on their migratory behavior than the mechanisms they use to mediate suppression. Importantly, the relative importance of specific mechanisms of T reg function and whether T regs possess mechanistic flexibility have not been elucidated. Previous studies have reported that deficiency of IL-10 or IL-35 alone results in defective T reg function (16, 18) . Thus, our finding that T regs lacking IL-35 and IL-10 are fully functional, instead of relying on TRAIL-mediated suppression as a primary mechanism of action, was very surprising. This implies that T regs can exhibit remarkable functional plasticity and possess control mechanisms to compensate for the loss of key regulatory tools.
There is a reciprocal relationship in the expression of IL-10 and CTSE (47) . Our data clearly show that Ebi3 2/2 Il10 2/2 T regs are dependent on TRAIL for their regulatory function in vitro and in vivo. Furthermore, our studies suggest that increased expression of CTSE enhances the rate and extent of TRAIL surface expression and TRAIL function in mediating T cell suppression. It is possible that CTSE may process full-length TRAIL to enhance its ligand binding and/or may mediate the cleavage of cell surface TRAIL to generate a soluble version. Soluble TRAIL is thought to be either secreted into microvesicles (48) or cleaved from the cell surface (49) . Whereas the precise mechanism by which CTSE enhances TRAIL function requires further elucidation, consistent with our results, previous studies have shown that proteolytic cleavage of TRAIL from the cell surface can be mediated by CTSE (35, 36 An important question is whether the extent of the physiological impact of the T reg functional plasticity revealed in our study has applicability. As shown in this study and previous studies, substantial differences in CTSE expression occur in different mouse strains with BALB/c mice expressing high levels of CTSE and C57BL/6 mice expressing low levels (21, 45) . Interestingly, BALB/c T regs appeared to phenocopy Ebi3 2/2 Il10 2/2 T regs in terms of their pattern of CTSE and TRAIL expression and, thus, their dependence on TRAIL-mediated suppression. Although there are certainly multiple genetic factors that might underlie differences in the function of T regs from distinct genetic backgrounds, our data suggest differential CTSE expression may be one contributing factor. Whether this is related to the necessity of T regs to adapt to the different Th cell bias exhibited in different mouse strains remains to be determined (50, 51) . Given that previous studies have shown that T regs can use different transcription factors to tackle different Th environments (10) (11) (12) , it is possible that these may underlie the differential utilization of T regsuppressive mechanisms observed in this study. This remarkable T reg functional plasticity may also be important in providing a backup mechanism in scenarios in which IL-10 and IL-35 production and/or signaling may be perturbed, and thus may empower T regs with the ability to adjust to different environmental settings. Lastly, the possibility that TRAIL may be a legitimate target for the treatment of diseases impacted by excessive T reg function, such as cancer, requires further study.
